Cynthia Smith's most recent trade in T. Rowe Price Group Inc. was a trade of 53 Common Stock done at an average price of $96.7 . Disclosure was reported to the exchange on June 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Group | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 96.72 per share. | 27 Jun 2025 | 53 | 6,567 (0%) | 0% | 96.7 | 5,126 | Common Stock |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 10,112 (0%) | 0% | 0 | Common stock | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 20,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 53,600 | 53,600 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 35,700 | 160,933 (0%) | 0% | 0 | Common Stock | |
| T. Rowe Price Group | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 2,157 | 6,514 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2025 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| T. Rowe Price Group | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 94.16 per share. | 28 Mar 2025 | 25 | 4,357 (0%) | 0% | 94.2 | 2,354 | Common Stock |
| T. Rowe Price Group | Cynthia Smith F. | Director | Grant, award, or other acquisition of securities at price $ 119.68 per share. | 27 Dec 2024 | 19 | 4,331 (0%) | 0% | 119.7 | 2,274 | Common Stock |
| T. Rowe Price Group | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 112.40 per share. | 27 Sep 2024 | 20 | 4,311 (0%) | 0% | 112.4 | 2,248 | Common Stock |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 7,992 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 2,302 | - | - | Restricted stock units | |
| T. Rowe Price Group | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 117.11 per share. | 27 Jun 2024 | 19 | 4,291 (0%) | 0% | 117.1 | 2,225 | Common Stock |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 5,690 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 30,000 | 125,233 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| T. Rowe Price Group | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 1,794 | 4,272 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 2,302 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 4,604 | - | - | Restricted stock units | |
| T. Rowe Price Group | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2023 | 2,478 | 2,478 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 30,000 | 95,233 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 37,947 | 37,947 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 6,906 | 6,906 | - | - | Restricted stock units | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 13,700 | 65,233 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 13,700 | 51,533 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 3,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 2,629 | 2,629 | - | - | Stock Option (right to buy) | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) |